Key result
Corticosteroid treatment for misdiagnosed juvenile polymyositis triggered proximal lower limb muscular weakness in a 14-year-old male with pre-symptomatic dysferlinopathy.
Why the study?
Diagnostic criteria can misclassify muscular dystrophies with inflammation as polymyositis, leaving dysferlinopathy patients vulnerable to misdiagnosis and inappropriate immunosuppressive therapy.
Case Report (n=1)
Muscular dystrophy must be ruled out before diagnosing juvenile polymyositis to avoid inappropriate treatment with steroids and immunosuppressors.
May warrant genetic testing before steroids in suspected juvenile polymyositis; extends LGMDR2 phenotype but leaves open need for validation.
BACKGROUND: Dysferlinopathy encompasses a group of rare muscular dystrophies caused by recessive mutations in the DYSF gene. The phenotype ranges from asymptomatic elevated serum creatine kinase (hyperCKemia) to selective and progressive involvement of the proximal and/or distal muscles of the limbs. Bohan and Peter criteria are the most widely used for the diagnosis of polymyositis, but they have limitations and can misclassify muscular dystrophies with inflammation as polymyositis. Most dysferlinopathy patients have muscle biopsies with inflammation and thus are vulnerable to misdiagnosis with polymyositis and inappropriate treatment with steroids and immunosuppressors. CASE PRESENTATION: We describe a 14 years-old male patient who was referred for assessment of asymptomatic hyperCKemia (26,372 IU/L). An X-linked dystrophinopathy initially was ruled out by direct genetic testing. Juvenile polymyositis was considered based on muscle biopsy, creatine kinase levels, and electromyography changes. Corticosteroid treatment triggered proximal lower limb muscular weakness, and no full muscular strength recovery was observed after corticosteroid withdrawal. Based on these observations, a limb-girdle muscular dystrophy (LGMD) was suspected, and LGMDR2 was confirmed by whole exome sequencing. CONCLUSION: We report a dysferlinopathy patient who was misdiagnosed with juvenile polymyositis and explore in a literature review how common such misdiagnoses are. With diagnosis based only on routine clinicopathological examinations, distinguishing an inflammatory myopathy from dysferlinopathy is quite difficult. We suggest that before establishing a diagnosis of "definite" or "probable" juvenile polymyositis, according to Bohan and Peter or current ACR/EULAR criteria, a muscular dystrophy must first be ruled out.
No takes yet. Share an insight, caveat, or question.
Contreras-Cubas et al. (2022) conducted a case report in Dysferlinopathy misdiagnosed as juvenile polymyositis (n=1). Corticosteroid treatment was evaluated on Clinical response to corticosteroid treatment. Corticosteroid treatment for misdiagnosed juvenile polymyositis triggered proximal lower limb muscular weakness in a 14-year-old male with pre-symptomatic dysferlinopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: